Refereed conference paper presented and published in conference proceedings
香港中文大学研究人员 ( 现职)
| 陈林教授 (肿瘤学系) |
| 马碧如教授 (肿瘤学系) |
全文
| 没有全文档案提供 |
引用次数
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/0Scopus source URL
其它资讯
摘要The discovery of the etiological link between cancers and oncogenic viruses has resulted in major breakthroughs in the development of preventive and therapeutic strategies against these cancers. The most significant achievement in the last decade has been the introduction of vaccines against HBV and HPV, which have led to a substantial reduction in the incidence of HCC and cervical cancer, respectively. Newer generations of preventive vaccines with broader antiviral coverage and potency are now under development. For patients with established cancers, such as EBV-associated lymphoma and NPC, adoptive immunotherapy has shown promising results in early-phase trials and should be further explored. Target-based agents are still at an early stage of development in NPC, and more studies are needed to identify biomarkers of response to improve patient selection. Given the preclinical evidence that certain target-based therapies may enhance the anticancer effect of chemotherapy or immunotherapy in EBV-associated cancers, these agents should be evaluated in combination or in sequence in future clinical trials. ? Thomson Reuters (Scientific) Ltd.
着者Ma B.B.Y., Chan S.L.
出版年份2http://aims.cuhk.edu.hk/converis/portal/Publication/0http://aims.cuhk.edu.hk/converis/portal/Publication/09
月份2
日期1
卷号12
期次2
出版社Current Drugs Ltd.
出版地United Kingdom
页次69 - 72
国际标準期刊号1369-7http://aims.cuhk.edu.hk/converis/portal/Publication/056
语言英式英语
